Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV squamous cell head and neck cancer~  * T3-4, N0-3, M0~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance Status:~* ECOG 0-2~Life Expectancy:~* Not specified~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 3.0 mg/dL~* SGOT no greater than 3 times upper limit of normal~Renal:~* Creatinine no greater than 3.0 mg/dL~Other:~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No concurrent beta-adrenergic blocking agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, amifostine, RT (Type: EXPERIMENTAL): Dose-escalation arm for paclitaxel with amifostine and RT.

Based on this trial design, predict the completion outcome and termination type (if applicable).